Analyzing Aadi Bioscience (NASDAQ:AADI) & Statera Biopharma (NASDAQ:STAB)

Statera Biopharma (NASDAQ:STAB) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Statera Biopharma and Aadi Bioscience’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	$1.49 million	0.03	-$101.85 million	N/A	N/A
Aadi Bioscience	$24.35 million	1.92	-$65.76 million	($2.44)	-0.78

Aadi Bioscience has higher revenue and earnings than Statera Biopharma.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Statera Biopharma and Aadi Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Statera Biopharma	0	0	0	0	N/A
Aadi Bioscience	0	1	1	0	2.50

Aadi Bioscience has a consensus price target of $24.67, suggesting a potential upside of 1,198.25%. Given Aadi Bioscience’s higher probable upside, analysts clearly believe Aadi Bioscience is more favorable than Statera Biopharma.

Profitability

This table compares Statera Biopharma and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Aadi Bioscience	-270.04%	-52.53%	-44.29%

Insider & Institutional Ownership

52.1% of Aadi Bioscience shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by insiders. Comparatively, 35.8% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Statera Biopharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Summary

Aadi Bioscience beats Statera Biopharma on 8 of the 11 factors compared between the two stocks.

About Statera Biopharma

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.